Clinical study evaluating the efficacy and safety of Cilostazol as an adjuvant therapy to methotrexate on patients with rheumatoid arthritis
Inflammopharmacology · 2025
DOI: 10.1007/s10787-025-01782-2 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Inflammopharmacology, 2025. Verfasst von Samar M Eldadamony und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt. samer.abdelfattah99@gmail.com. Hauptthemen laut MEDLINE: Cilostazol, Arthritis, Rheumatoid, Methotrexate, Antirheumatic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tanta University.
Abstract (Originalsprache)
Objective
This study aims to assess the safety as well as effectiveness of Cilostazol as a complementary therapy to methotrexate among individuals with active rheumatoid arthritis.
Method
This study was a randomly allocated, double-blind, placebo-controlled parallel design involving 70 patients who were diagnosed with active rheumatoid arthritis. Participants were randomly assigned to two sets: the control group ( n = 35) which received methotrexate "MTX" (7.5 mg IM weekly) plus placebo tablets twice daily and the Cilostazol group ( n = 35), which received the same MTX" dose plus Cilostazol 50 mg twice daily for 3 months. Patients were assessed to determine the serum levels of C-reactive protein (CRP) nuclear factor kappa B (NF-κB), hemoxygenase-1 (HO-1), and cyclic adenosine monophosphate (cAMP). Disease Activity Score (DAS28-CRP), Multidimensional Health Assessment Score (MDHAQ), and morning stiffness duration were also assessed.
Results
The Cilostazol group produced a significant improvement in cAMP level as compared to the control group ( P = 0.001) . cAMP level showed a significant inverse correlation with DAS28-CRP ( r = −0.336; P = 0.004). However, Cilostazol group produced non-significant improvements in the serum levels of the other biological markers (CRP, NF-κB, and HO-1), DAS28-CRP score, MDHAQ score, and morning stiffness duration as compared to the control group (P > 0.05). The implication of Cilostazol for patients with rheumatoid arthritis was tolerable and safe.
Conclusion
The beneficial effect of Cilostazol on cAMP and the negative correlation between cAMP and DAS28-CRP could support its impact on the disease activity. Further research seems necessary to elucidate the mechanisms underlying the link between cAMP and disease activity.
Trial registration
Clinical Trials.gov identifier: NCT05594680 , The date of registration is: 30/10/2022.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt. samer.abdelfattah99@gmail.com.
- Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
- Department of Rheumatology, Rehabilitation and Physical Medicine, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Förderung
- Tanta University
Zitieren
APA
Eldadamony, S. M., El-Haggar, S. M., Ali, A. M. A., & Mostafa, T. M. (2025). Clinical study evaluating the efficacy and safety of Cilostazol as an adjuvant therapy to methotrexate on patients with rheumatoid arthritis. Inflammopharmacology. https://doi.org/10.1007/s10787-025-01782-2
Vancouver
Eldadamony SM, El-Haggar SM, Ali AMA, Mostafa TM. Clinical study evaluating the efficacy and safety of Cilostazol as an adjuvant therapy to methotrexate on patients with rheumatoid arthritis. Inflammopharmacology. 2025. doi:10.1007/s10787-025-01782-2
BibTeX
@article{Eldadamony2025,
author = {Eldadamony, Samar M and El-Haggar, Sahar M and Ali, Abdel Moaty A and Mostafa, Tarek M},
title = {Clinical study evaluating the efficacy and safety of Cilostazol as an adjuvant therapy to methotrexate on patients with rheumatoid arthritis},
journal = {Inflammopharmacology},
year = {2025},
doi = {10.1007/s10787-025-01782-2}
}
EUVIMED